Delivery Order SPE2DB20D2014-SPE2DB25FA80M

Award Date 1/14/25
Potential Completion Date 1/15/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TRESIBA FLEXTOUCH 100 UNIT/ML 3ML, a pharmaceutical product, with a ceiling value of $1,392.98 and a period of performance ending on April 4, 2025. The contract is a Delivery Order issued under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award is for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., for a ceiling value of $11,864.96. The contract is a delivery order with a firm fixed price and has a period of performance through February 23, 2024. It was awarded on February 22, 2024, and does not have a set-aside designation,...
This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical is a delivery order placed with AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for TRESIBA FLEXTOUCH 100 UNIT/ML 3ML. The contract has a firm fixed price of $2,782.23 and a completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This federal contract award is for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $10,184.64, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm-fixed-price delivery order with a completion date of November 26, 2024. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a...
This federal contract award is for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $5,952.20 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., doing business as Amerisourcebergen. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, which serves as the primary...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML, a specialty medication. The contract has a ceiling value of $5,553.84 and is a Firm Fixed Price Delivery Order, with an ultimate completion date of March 13, 2025. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant Indefinite...
This federal contract award, valued at $2,076.30, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TRESIBA FLEXTOUCH 100 UNIT/ML 3ML, a medical supply product, with a completion date of January 15, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued...
This federal contract award, valued at $2,957.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the procurement of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML, a medical product, with a completion date of December 21, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This contract award is for the delivery of TRESIBA FLEXTOUCH 100 UNIT/ML 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $1,384.20. It is a delivery order contract with a firm fixed price pricing type, and the ultimate completion date is March 4, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug...
This federal contract award, valued at $36,069.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML, a medical product, to support federal healthcare programs. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB25FA80M
    Delivery Order

The federal contract award is for the delivery of TRESIBA FLEXTOUCH 200 UNIT/ML 3ML pharmaceutical products, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract has a ceiling value of $10,369.20 and is a firm-fixed-price delivery order with a completion date of January 15, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 10:30 AM